Information Provided By: 
Fly News Breaks for April 15, 2016
ABMD
Apr 15, 2016 | 08:43 EDT
Leerink analyst Danielle Antalffy believes Abiomed's shares will continue to move higher, despite a healthy valuation. Antalffy says the company is "well-positioned" to deliver "strong" double-digit sales growth over the near to mid-term, as it drives increasing penetration into the prophylactic high-risk percutaneous coronary intervention and cardiogenic shock patient populations, benefits from new products and continues to add new centers in the U.S. The analyst reiterates an Outperform rating and $120 price target on the shares.
News For ABMD From the Last 2 Days
There are no results for your query ABMD
